{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:14:42Z","timestamp":1789038882145,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,10,7]],"date-time":"2010-10-07T00:00:00Z","timestamp":1286409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Blood donor screening with enzyme immunoassays (EIAs) for antibodies to human T\u2010lymphotropic virus (HTLV)\u2010I, and later to HTLV\u2010I\/II, has led to the unnecessary deferral of tens of thousands of individuals. The licensure of the Abbott PRISM HTLV\u2010I\/HTLV\u2010II chemiluminescent immunoassay (ChLIA) may permit the reinstatement of historically deferred donors.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> The efficacy of a reentry algorithm involving a follow\u2010up sample from EIA\u2010deferred donors testing HTLV\u2010I\/II ChLIA nonreactive was evaluated using 386 serologic confirmed\u2010positive samples archived since the inception of anti\u2010HTLV donor screening. Reactivity of the 386 samples by the ChLIA, when coupled with the package insert sensitivity data, may be used to demonstrate efficacy of the reentry algorithm. Donor incidence was also examined from 2008 through 2009 to evaluate changes to the existing HTLV screening policy.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> From January 1, 1995, to April 28, 2008, a total of 64,052 donors to the American Red Cross were deferred solely because of HTLV EIA false positivity, representing more than 130,000 US donors. HTLV ChLIA identified 386 confirmed\u2010positive donations from 386 randomly selected donors representing reactivity to both the bioM\u00e9rieux and the Abbott HTLV\u2010I\/II EIAs (95% confidence interval [CI], 99.2%\u2010100%); both EIAs have since been discontinued. This is comparable to the detection of 843 of 843 confirmed\u2010positive samples during the ChLIA clinical trials (95% CI, 99.48%\u2010100%). Incident HTLV infections occurred primarily among female repeat donors during 2008 throughout 2009.<\/jats:p><jats:p><jats:bold>CONCLUSIONS:<\/jats:bold> Donors testing falsely positive by historic EIAs since 1988 should be considered for reinstatement if a contemporary sample tests ChLIA nonreactive. Changes to the existing screening algorithm seem unlikely since new HTLV infections were detected among repeat donors.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2010.02903.x","type":"journal-article","created":{"date-parts":[[2010,10,7]],"date-time":"2010-10-07T16:52:17Z","timestamp":1286470337000},"page":"692-701","source":"Crossref","is-referenced-by-count":32,"title":["Human T\u2010lymphotropic virus antibody screening of blood donors: rates of false\u2010positive results and evaluation of a potential donor reentry algorithm"],"prefix":"10.1111","volume":"51","author":[{"given":"Susan L.","family":"Stramer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Notari IV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Krysztof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaye P.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary E.","family":"Tegtmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger Y.","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,10,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00788.x"},{"key":"e_1_2_7_3_2","first-page":"173","article-title":"False\u2010positive serologic tests for human T\u2010cell lymphotropic virus type I among blood donors following influenza vaccination, 1992","volume":"42","author":"Centers for Disease Control and Prevention (CDC)","year":"1993","journal-title":"MMWR"},{"key":"e_1_2_7_4_2","first-page":"2071","volume-title":"Fields virology","author":"Lairmore MD","year":"2007"},{"key":"e_1_2_7_5_2","first-page":"447","volume-title":"Blood banking and transfusion medicine: basic principles and practice","author":"Fiebig EW","year":"2009"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1001.020714"},{"key":"e_1_2_7_7_2","first-page":"30S","article-title":"False positive EIA reactivity in multiple blood bank screening assays is due to non\u2010specific binding of IgM [Abstract no. S111]","volume":"32","author":"Stramer SL","year":"1992","journal-title":"Transfusion"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-6-199303150-00009"},{"key":"e_1_2_7_9_2","unstructured":"Food and Drug Administration (FDA).Donor screening for antibodies to HTLV\u2010II. FDA guidance for industry August 1997. [cited 2010 Apr 5]. Available from: URL:http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Blood\/UCM170916.pdf"},{"key":"e_1_2_7_10_2","unstructured":"AABB.Dual enzyme immuno assay (EIA) approach for deferral and notification of anti\u2010HTLV\u2010I\/II EIA reactive donors. AABB Association Bulletin #99\u20109 September1999."},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00174.x"},{"key":"e_1_2_7_12_2","volume-title":"SAS JMP","year":"2000"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2008.01136.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910510609"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199703010-00011"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/315139"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01760.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199308193290816"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199312303292712"},{"key":"e_1_2_7_20_2","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood.V83.4.1143.1143","article-title":"Accuracy of supplementary serologic testing for human T\u2010lymphotropic virus types I and II in US blood donors. Retrovirus Epidemiology Donor Study","volume":"83","author":"Busch MP","year":"1994","journal-title":"Blood"},{"key":"e_1_2_7_21_2","first-page":"715","article-title":"Detection of human T\u2010lymphotropic virus (HTLV) tax sequences in New York city blood donors seronegative for HTLV types 1 and 2","volume":"10","author":"Dezzutti CS","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.1997.7230144.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39111185.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00114.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0037-86822010000200001"},{"key":"e_1_2_7_26_2","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/archinte.1991.00400100115019","article-title":"Transmission of human T\u2010lymphotropic virus types I and II by blood transfusion. A retrospective study of recipients of blood components (1983 through 1988). The American Red Cross HTLV\u2010I\/II Collaborative Study Group","volume":"151","author":"Sullivan MT","year":"1991","journal-title":"Arch Intern Med"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1993.33193142303.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2010.02903.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2010.02903.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T09:40:17Z","timestamp":1697276417000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2010.02903.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1111\/j.1537-2995.2010.02903.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2010.02903.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,7]]}}}